Acorda Therapeutics Market Cap: 1.01B
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
None selected
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
ACOR Market Cap Rankings
| Overall | 60th percentile | 1845 of 4673 |
| Sector | 73rd percentile | 140 of 530 in Healthcare |
| Industry | 82nd percentile | 29 of 164 in Biotechnology |
ACOR Market Cap Range, Past 5 Years
| Minimum | 81.82M | Jun 2006 |
| Maximum | 362.10M | Dec 2006 |
| Average | 180.74M |
About Market Capitalization
Market Capitalization (Market Cap) is a measurement of business value based on share price and number of shares outstanding. It generally represents the market's view of a company's stock value and is a determining factor in stock valuation.
For example, if a company has 1.5 million shares outstanding at a share price of $25, its market cap is $37.5 million (1.5 million x $25). Companies can be categorized based upon the size of their market capitalization.
There are five basic groups: mega-cap (market cap over $200B), large-cap ($10B–$200B), mid-cap ($2B–$10B), small-cap ($300M–$2B), and micro-cap ($50M-$300M). Market cap is not always an accurate indication of value because it does not account for debt and other factors.
Learn More
You may also be interested in these ACOR related companies
ACOR News
A Forward Look, the Year Ahead - Featured Research on Acorda Therapeutics Inc and Abbott Laboratories
Feb 09, 9:00AM Marketwire
Feb 09, 9:00AM Marketwire
Acorda Therapeutics to Present at Leerink Swann 2012 Global Healthcare Conference
Feb 09, 6:01AM Business Wire
Feb 09, 6:01AM Business Wire
$REGN is one just started shorting since hitting near $102 mon, little scalps have netted a few pts , has ER next wk with $ACOR & $NPSP
about 4 days ago by ronin245
about 4 days ago by ronin245
Acorda Therapeutics to Present at 14th Annual BIO CEO & Investor Conference
Feb 07, 6:00AM Business Wire
Feb 07, 6:00AM Business Wire
Acorda Therapeutics Announces Launch of Authorized Generic Version of ZANAFLEX CAPSULES®
Feb 06, 4:15PM Benzinga
Feb 06, 4:15PM Benzinga
VERY handy JP Morgue Healthcare Conf. Schedule: http://stks.co/1q3x $DNDN $ONXX $REGN $ACOR - the lot of them $$
about 34 days ago by Shoofly7
about 34 days ago by Shoofly7
Acorda Therapeutics Provides 2012 Corporate Update at 30th Annual J.P. Morgan Healthcare Conference
Jan 09, 6:00AM Business Wire
Jan 09, 6:00AM Business Wire
$ACOR 200 Day SMA Cross - Price crossed below 200 day SMA (25.4272). Confirmed by volume.
about 38 days ago by TradeIdeasQuant
about 38 days ago by TradeIdeasQuant
$ACOR 200 Day SMA Cross - Price crossed above 200 day SMA (25.4272). Confirmed by volume.
about 38 days ago by TradeIdeasQuant
about 38 days ago by TradeIdeasQuant
Acorda Therapeutics to Present at the 30th Annual J.P. Morgan Healthcare Conference
Dec 28, 6:00AM Business Wire
Dec 28, 6:00AM Business Wire
RT @sssc potential long on top side push: $ACOR http://stks.co/1Rvj tnx
about 66 days ago by StockTiger
about 66 days ago by StockTiger
Acorda Therapeutics to Present at the Piper Jaffray 23rd Annual Healthcare Conference
Nov 22, 6:00AM Business Wire
Nov 22, 6:00AM Business Wire
$ACOR http://chart.ly/6b9w8lb On my watch list to go long, in case mkt favors tomorrow.
about 186 days ago by vjtweet
about 186 days ago by vjtweet
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| ACOR | 25.44 | -0.38 | -1.47% | 1.01B |
| BPOP | 1.68 | -0.09 | -5.08% | 1.72B |
| ATML | 9.78 | -0.11 | -1.11% | 4.52B |
| ALSK | 2.81 | -0.02 | -0.71% | 127.01M |
| VZ | 37.69 | -0.23 | -0.61% | 106.70B |
| HTCH | 2.10 | -0.14 | -6.25% | 49.14M |
| GSIT | 4.80 | -0.06 | -1.23% | 137.42M |
| AMAT | 12.95 | -0.16 | -1.22% | 17.06B |
| SHLD | 47.57 | -0.82 | -1.69% | 5.09B |
| OVRL | 2.10 | -0.01 | -0.47% | 48.45M |
